What is William Blair's Estimate for PTCT FY2025 Earnings?

Key Points

• William Blair has lowered its FY2025 earnings per share forecast for PTC Therapeutics to $6.00 from $6.14, while the current consensus estimate indicates a loss of $4.52 per share.
• During its last quarterly report, PTC Therapeutics posted an EPS of $10.04, significantly exceeding analysts' expectations and revealing a net margin of 33.56% despite a 9.6% decline in revenue year-over-year.
• A range of analysts have adjusted their price targets for PTC Therapeutics, with some raising their price objectives, indicating a generally positive outlook despite the recent earnings forecast downgrade.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Investment analysts at William Blair reduced their FY2025 earnings per share (EPS) estimates for shares of PTC Therapeutics in a note issued to investors on Tuesday, July 29th. William Blair analyst S. Corwin now expects that the biopharmaceutical company will post earnings of $6.00 per share for the year, down from their previous forecast of $6.14. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $9.19. The business had revenue of $1.18 billion during the quarter, compared to analysts' expectations of $437.16 million. PTC Therapeutics had a negative return on equity of 78.56% and a net margin of 33.56%. The business's quarterly revenue was down 9.6% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.20) EPS.

Several other research firms have also recently issued reports on PTCT. Wall Street Zen cut PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 16th. Royal Bank Of Canada upped their target price on PTC Therapeutics from $57.00 to $58.00 and gave the company an "outperform" rating in a research report on Wednesday, May 7th. Bank of America upped their target price on PTC Therapeutics from $68.00 to $84.00 and gave the company a "buy" rating in a research report on Tuesday. Citigroup upped their target price on PTC Therapeutics from $40.00 to $50.00 and gave the company a "neutral" rating in a research report on Monday. Finally, Wells Fargo & Company upped their target price on PTC Therapeutics from $74.00 to $78.00 and gave the company an "overweight" rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, PTC Therapeutics has an average rating of "Moderate Buy" and an average target price of $69.38.

PTC Therapeutics Stock Performance

Shares of NASDAQ:PTCT traded up $1.17 on Wednesday, hitting $52.11. 2,303,602 shares of the company's stock were exchanged, compared to its average volume of 1,023,425. The firm's 50-day moving average is $48.95 and its 200 day moving average is $48.58. The company has a market capitalization of $4.13 billion, a PE ratio of 8.00 and a beta of 0.50. PTC Therapeutics has a 1-year low of $29.01 and a 1-year high of $58.38.

Institutional Trading of PTC Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Sterling Capital Management LLC increased its position in shares of PTC Therapeutics by 424.4% during the fourth quarter. Sterling Capital Management LLC now owns 645 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 522 shares during the last quarter. Quantbot Technologies LP increased its holdings in PTC Therapeutics by 545.5% in the first quarter. Quantbot Technologies LP now owns 652 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 551 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in PTC Therapeutics by 84.2% in the first quarter. PNC Financial Services Group Inc. now owns 700 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 320 shares during the last quarter. GAMMA Investing LLC increased its holdings in PTC Therapeutics by 86.3% in the first quarter. GAMMA Investing LLC now owns 952 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 441 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in PTC Therapeutics in the first quarter valued at about $61,000.

Insider Transactions at PTC Therapeutics

In other news, CFO Pierre Gravier sold 2,516 shares of PTC Therapeutics stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $49.46, for a total transaction of $124,441.36. Following the sale, the chief financial officer directly owned 71,920 shares of the company's stock, valued at approximately $3,557,163.20. The trade was a 3.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Mark Elliott Boulding sold 1,929 shares of PTC Therapeutics stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $46.18, for a total value of $89,081.22. Following the sale, the vice president directly owned 103,901 shares in the company, valued at approximately $4,798,148.18. The trade was a 1.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 5,328 shares of company stock worth $254,158. 5.50% of the stock is currently owned by insiders.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.